ALLO-501A-201: A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refractory Large B Cell Lymphoma (LBCL). (Alpha2 Study)

There are 2 unapproved agents being evaluated in this study: ALLO-501A, and ALLO-647, which are used together and are being evaluated as a treatment for lymphoma. ALLO-647 is an antibody that will decrease certain white blood cells in your body in preparation to receive the ALLO-501A cells that target your lymphoma. ALLO-647 is given with chemotherapy drugs fludarabine (F) and cyclophosphamide (C). ALLO-501A is genetically modified white blood cells from a healthy person (donor) designed to target and treat lymphoma. The goal of this study is to see how well ALLO-501A treats the disease when given after a lymphodepletion regimen containing ALLO-647 along with the chemotherapy agents fludarabine (F) and cyclophosphamide (C).